Table 3.
Characteristics of the blood donors identified with resistance-associated mutations.
| Sample ID | Gender | Age | Donation | Ethnicity | Education | Genotype | PI accessory DRMs | PI major DRMs | NNRTI DRMs | Drug resistance |
|---|---|---|---|---|---|---|---|---|---|---|
| Henan-011 | Male | 24 | First-time | Han | Associate degree | URF (PR-RT: CRF79_0107) | M46R | — | ||
| Henan-016 | Male | 46 | Repeated | Han | Secondary school or below | CRF07_BC | Q58E | PLLR to NFV; LLR to TPV | ||
| Beijing-045 | Male | 34 | Repeated | Han | Master/Bachelor degree | CRF07_BC | Q58E | PLLR to NFV; LLR to TPV | ||
| Shenzhen-010 | Male | 26 | First-time | Han | Secondary school or below | CRF07_BC | Q58E | PLLR to NFV; LLR to TPV | ||
| Tongzhou-115 | Male | 29 | First-time | Han | Associate degree | URF (PR-RT: B) | M46L | V106I | PLLR to ATV, FPV, IDV, LPV, SQV, TPV, ETR, NVP and RPV; LLR to NFV and DOR | |
| Harbin-007 | Male | 19 | First-time | Han | Master/Bachelor degree | CRF01_AE | M46I* | PLLR to ATV, FPV, IDV, LPV andSQV; IR to NFV | ||
| Shenzhen-011 | Male | 22 | First-time | Han | Secondary school or below | CRF01_AE | N88S | HLR to ATV and NFV, LLR to IDV and SQV | ||
| Tongzhou-017 | Male | 31 | First-time | Han | Associate degree | CRF07_BC | K101E* | IR to NVP and RPV; PLLR to DOR, EFV and ETR | ||
| Tongzhou-025 | Male | 53 | First-time | Han | Associate degree | URF (PR-RT: CRF79_0107) | K103N* | HLR to EFV and NVP | ||
| Tongzhou-126 | Male | 39 | First-time | Han | Associate degree | URF (PR-RT: CRF01_AE) | K103N* | HLR to EFV and NVP | ||
| Shenzhen-019 | Male | 31 | First-time | Han | Master/Bachelor degree | CRF01_AE | V179D + K103R | IR to EFV and NVP; PLLR to ETR; LLR to RPV | ||
| Tongzhou-022 | Male | 43 | First-time | Han | Associate degree | CRF65_cpx | V179D + K103R | IR to EFV and NVP; PLLR to ETR; LLR to RPV | ||
| Henan-005 | Male | 50 | First-time | Han | Secondary school or below | URF (PR-RT: CRF07_BC) | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Henan-020 | Male | 35 | First-time | Han | Secondary school or below | CRF07_BC | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Chongqing-008 | Female | 48 | Repeated | Han | Secondary school or below | CRF07_BC | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Chongqing-015 | Male | 50 | First-time | Han | Secondary school or below | CRF08_BC | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Changchun-066 | Male | 20 | First-time | Han | Master/Bachelor degree | URF (PR-RT: CRF07_BC) | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Changchun-074 | Male | 24 | First-time | Han | Associate degree | CRF01_AE | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Shaanxi-063-NAT | Male | 28 | First-time | Han | Secondary school or below | CRF07_BC | V179D | PLLR to EFV, ETR, NVP and RPV | ||
| Henan-019 | Male | 31 | First-time | Han | Secondary school or below | URF (PR-RT: CRF55_01B) | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Chongqing-003 | Male | 57 | Repeated | Han | Secondary school or below | CRF55_01B | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Chongqing-005 | Male | 26 | First-time | Han | Secondary school or below | CRF08_BC | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Harbin-004 | Male | 29 | Repeated | Han | Associate degree | B | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Harbin-022 | Male | 35 | First-time | Han | Secondary school or below | URF (PR-RT: CRF55_01B) | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Shaanxi-022 | Male | 40 | First-time | Han | Associate degree | CRF55_01B | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Shenzhen-012-2018 | Male | 29 | First-time | Han | Secondary school or below | CRF55_01B | V179E | PLLR to EFV, ETR, NVP and RPV | ||
| Chongqing-011 | Male | 40 | Repeated | Minority | Secondary school or below | CRF01_AE | V179T | — | ||
| Jiangsu-010 | Male | 39 | First-time | Han | Associate degree | CRF01_AE | V179T | — |
*Sequences with surveillance drug-resistance mutations (SDRMs).
1. The interpretation system reports five different possible levels of drug resistance(https://hivdb.stanford.edu/): Susceptible, Potential low-level resistance (PLLR), Low-level resistance (LLR), Intermediate resistance (IR) and High-level resistance (HLR).
2. Unique recombinant form (URF); Protease Inhibitors (PIs): Atazanavir (ATV), Darunavir (DRV), Fosamprenavir (FPV), Indinavir (IDV),Lopinavir (LPV), Nelfinavir (NFV), Saquinavir (SQV), Tipranavir (TPV); Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Doravirine (DOR), Efavirenz (EFV), Etravirine (ETR), Nevirapine (NVP), Rilpivirine (RPV).
3. The combination of V179D and K103R defined as NNRTI DRM act synergistically to reduce EFV and NVP susceptibility.
4. M46R is a highly unusual mutation at this position, V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs, the details about drug resistance are not shown in Stanford University HIV DRUG RESISTANCE DATABASE (https://hivdb.stanford.edu/).